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Rituximab, a chimeric monoclonal antibody (mAb) which targets
the CD20 molecule on the B-cell surface, was the first antibody to
be licensed for the treatment of malignancy. This represents the
culmination of more than two decades of intensive investigation
into the use of mAb in lymphoma, and points the way to a new
era of cancer-specific therapy. There are many questions still
outstanding about the precise cellular effects of the antibody, but
emerging clinical data suggest that it may represent a step forward
in the treatment of B-cell malignancies. Unfortunately the applica-
tion of rituximab is running well ahead of the evidence, with 30
000 patients per annum receiving it in the USA at a cost of over
$400 million in 2000, a figure which is rising steeply. As many as
80% of newly diagnosed patients with large cell lymphoma are
reported to be receiving treatment including the antibody, despite
the absence of any fully published evidence of efficacy in a
randomised trial. This situation needs to be corrected as rapidly as
possible, and it will be important to complete the trials now
underway. 
MECHANISMS OF ACTION 
It is likely that the action of rituximab against lymphoma is due as
much to direct signalling in the malignant B-cells following CD20
ligation as to recruitment of effectors such as complement and
antibody-directed cellular cytotoxicity (ADCC) (Vitetta and Uhr,
1994; Cragg et al, 1999; Ghetie et al, 2001). This is important
because it suggests that the combination of antibodies with 
chemo- or radio-therapy may enhance rather than diminish the
therapeutic effect. 
CD20 was one of the first B-cell-specific markers to be identi-
fied in the early investigations of the cell surface phenotype with
mAb (Stashenko et al, 1980). Although murine anti-CD20 
molecules were available for some time, their clinical application
was largely restricted to in vitro purging of bone marrow for 
transplantation, and later work with radioconjugates. The principal
limitations to their use in vivo were a short half-life, normally 
less than 20 hours, and the potential for stimulating human anti-
mouse antibodies (HAMA), resulting in the formation of circu-
lating immune complexes that were therapeutically inactive and
could cause severe adverse effects if generated in sufficient quan-
tity. It was only when molecular techniques allowed the generation
of chimeric mAb through replacement of the mouse constant
domains with human ones that the half life was extended to several
days and serial treatments were not impeded by HAMA responses. 
The CD20 molecule is a 33–37 kDa phosphoprotein with a
predicted structure comprising 4 transmembrane regions, a 44
amino acid extracellular loop and cytoplasmic N- and C-termini
(Einfeld et al, 1988). It was always an attractive target for mAb
therapy due to its high expression on almost all normal B cells and
B-cell malignancies and its resistance to internalisation or shed-
ding from the plasma membrane following ligation (Press et al,
1987). No natural ligand has been identified for CD20, and
progress in understanding the biology of the molecule has been
hampered by the inability to generate anti-mouse CD20 mAb.
CD20 knockout mice show no definitive phenotype (O’Keefe 
et al, 1998), but ligation of CD20 with mAb does result in a variety
of interesting events, including triggering of intracellular
signalling cascades and altered calcium transport. Furthermore,
stimulation of B cells with anti-CD20 mAbs and phorbol esters
results in enhanced phosphorylation of CD20, again suggesting a
role in transmembrane signalling and control of cell growth
(Tedder and Schlossman, 1988). Functional studies with a variety
of CD20 antibodies have shown modulatory effects on B cell acti-
vation, proliferation and differentiation (Golay et al, 1985;
Smeland et al, 1985), and activation of protein tyrosine kinases.
(Kansas and Tedder, 1991). There is limited evidence that CD20
functions as a calcium channel subunit (reviewed in Tedder and
Engel (1994)). This fits with findings that CD20 exists on the cell
surface as a homo-oligomer (Bubien et al, 1993), and regulates cell
cycle progression possibly through maintaining calcium levels and
thus inhibiting progress from G1 to S phase (Kanzaki et al, 1995).
Recent data show that ligation of CD20 with mAb leads directly to
apoptosis and appears to use the same intracellular pathway(s) as
apoptosis triggered via the B-cell receptor (Mathas et al, 2000).
This was most clearly demonstrated by the close correlation
between the sensitivity of various B-cell lines to anti-CD20- and
anti-BCR-mediated apoptosis and the similarities in the proapop-
totic proteins, such as BAX, that these reagents up-regulate. 
A variety of molecules appear to associate with CD20 in the cell
membrane. A complex of CD20, MHC class I and II, and members
of the TM4SF has been described (Szollosi et al, 1996), and other
studies have shown co-localisation with Src-family kinases Lyn,
Fyn and Lck (Deans et al, 1995). There is also evidence to suggest
that stimulation with anti-CD20 results in the redistribution of
CD20 into membrane rafts (Deans et al, 1998), with CD20 and the
Src-family kinases anchored in these (Casey, 1995). This redistri-
bution is accompanied by the appearance of an uncharacterised
50 kDa tyrosine-phosphorylated protein in the same compartment
(Polyak et al, 1998). Other B-cell growth-regulating effects seen
upon CD20 ligation include activation of phospholipase Cγ , inter-
ruption of the IL6/STAT 3 pathway (Alas and Bonavida, 2001) and
up-regulation of c-Myc. In addition, recent results have suggested
that engaging CD20 can inhibit production of IL10, which may act
as an autocrine growth factor as well as influencing the local T-cell
repertoire (Alas et al, 2001). 
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for Roche Pharmaceuticals.The effects of CD20 ligation have been studied mainly in trans-
formed B-cell lines, and little work has been carried out in isolated
primary cells from human lymphoma or in vivo. Rituximab is
unusually effective in both ADCC and complement-mediated
cytotoxicity, and in some cell lines at least, induces potent apop-
tosis when sufficiently crosslinked (Shan et al, 1998; Mathas et al,
2000). While the relative importance of these processes is not
known, Ravetch and colleagues have recently used immunoglob-
ulin constant region receptor (FcR)-deficient mice to show an
important role for both stimulatory and inhibitory FcR in medi-
ating the therapeutic activity of rituximab (Clynes et al, 2000). In a
series of elegant experiments this group demonstrated that full
therapeutic activity of rituximab and similar anti-cancer mAb was
only achieved in mice expressing stimulatory, γ -chain-associated,
Fcγ R. These data were consistent with FcR contributing signifi-
cantly to the antitumour activity in vivo. However, many mAb
which are highly active in ADCC, for example anti-CD19, have
failed to produce effects in clinical studies and it is clear that
multiple mechanisms are likely to operate in vivo. Interestingly,
even in γ -chain deficient mice, which do not express stimulatory
FcR and could not mediate ADCC, mAb still retain some thera-
peutic activity in various models (Clynes et al, 1998). Such
therapy could be due to complement-mediated killing, in which
rituximab is highly active, particularly against tumour cells
lacking or with blocked complement inhibitor molecules, CD55
and CD59 (Golay et al, 2000; Harjunpaa et al, 2000). It is also
possible that the direct cytotoxic activity of rituximab is important
and that FcR-expressing cells can influence this pathway. By
providing a multivalent array of FcR, even low-affinity receptors
will be able to hyper-crosslink Ab-coated target cells. Shan and
co-workers (Shan et al, 1998) have shown that FcR-expressing
effector cells, which increase crosslinking, can enhance apoptosis
induced by anti-CD20 mAb bound to B-cell targets. Likewise,
Mathas (Mathas et al, 2000) showed that while highly crosslinked
rituximab was very effective in inhibiting the growth of B-cell
lines, soluble anti-CD20 had little activity. 
In summary, it is evident that rituximab can control lymphoma
growth by several mechanisms, including ADCC, complement
activation and triggering direct intracellular signalling cascades.
The relative contribution of each of these in vivo remains uncer-
tain and is likely to keep immunologists busy for some time to
come. 
CLINICAL APPLICATION 
The earliest studies tested rituximab alone as a treatment for recur-
rent CD20+ lymphoma. A dose of 375 mg m–2 weekly for 4 weeks
was established as the standard. A small randomised trial
comparing a higher dose of 500 mg m–2 did not show a significant
difference in response rates (Coiffier et al, 1998). The ‘pivotal’
study included 166 patients with lymphoma of Working
Formulation grades A–C in whom the disease had recurred despite
initially successful treatment, in many cases quite extensive
(McLaughlin et al, 1998). There was a response rate of 48%, with
a median response duration of 13 months, a result confirmed in
other similar studies from Europe. This treatment has now been
tested in the whole range of B-cell lymphomas, and the results are
summarised in Table 1. There is a modest response rate in diffuse
large cell and mantle cell lymphomas, but a rather lower rate in
lymphocytic lymphoma/CLL, possibly due to their lower density
of CD20 molecules. The approach of either increasing the dose of
antibody or prolonging the course of treatment has been tested in
this group, with some suggestion of a higher response rate in phase
II studies (Byrd et al, 2001; O’Brien et al, 2001). In all disease
types the responses are of limited duration, around a median of
1 year. 
The early studies confirmed the tolerable side-effect profile of
rituximab, with the only common serious events being infusion-
related hypotension, fever and rigors, seen almost entirely with the
first infusion and not recurring on continued treatment. Patients
with large numbers of circulating lymphoma cells are more likely
to suffer adverse effects, probably mediated by complement acti-
vation. The antibody has a substantial effect upon the numbers 
of circulating normal B-cells, but these recover after an interval 
of 3 – 6 months and there is consequently little impact upon
immunoglobulin levels. The incidence of opportunistic infection is
low. 
The moderate side-effect profile encouraged use of the antibody
as first-line therapy, and the studies which have been performed in
low-grade lymphoma suggest that the response rate may be up to
75% in this setting (Hainsworth et al, 2000; Colombat et al, 2001).
This observation may be particularly interesting for the group 
of patients with low-grade lymphoma for whom conservative
‘watchful waiting’ would normally be the approach, but in whom
prolonged remission might be achieved with brief duration low-
toxicity antibody therapy. Trials are in progress to test this. In this
context it is interesting that re-treatment with rituximab appears 
to be well tolerated, without substantially different side effects 
to those seen with the first course and a very low incidence of
antichimeric antibodies (Davis et al, 2000), so that use early in the
illness may not compromise later therapy. 
One outcome that has been extensively studied with monoclonal
antibody treatment is the ability to achieve ‘molecular remission’,
namely the eradication of polymerase chain reaction (PCR)-
detectable residual lymphoma cells as indicated by the presence of
a characteristic translocation such as the t(14;18) BCL2-IgH
rearrangement in follicular lymphoma or t(11;14) BCL1-IgH in
mantle cell lymphoma (Foran et al, 2000b; Colombat et al, 2001;
Czuczman et al, 2001). These tests are still unproven as surrogate
endpoints (Johnson et al, 1999), but a common observation is that
rituximab therapy is frequently capable of clearing the peripheral
blood and bone marrow of PCR-detectable cells, although lymph
node masses may remain. Thus in the French study of initial
therapy for follicular lymphoma 17 of 30 (57%) patients went
from BCL2-IgH PCR positive to negative in peripheral blood after
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Table 1 Responses of recurrent lymphoma to rituximab 
Study  Number of  % response  Median response
(Reference) patients rate duration (months) 
Pivotal: WF A-D  166 48 13
(McLaughlin et al, 
1998)
UK follicular  70 46 11 
(Foran et al, 2000b)
European mantle cell  87 34 12
(Foran et al, 2000a)
Small lymphocytic  28 14 NS
(Foran et al, 2000c)
Small lymphocytic  33 45 10 
(dose intense)
(Byrd et al, 2001)
European large Cell 30 37 > 8
(Coiffier et al, 1998)50 days, and at 12 months 16 of 26 (62%) remained PCR negative
(Colombat et al, 2001). Although PCR is of limited usefulness as a
predictive test in this setting, the results do suggest that clearing
the blood and bone marrow of disease prior to progenitor cell
harvesting may be possible with rituximab, and this approach is
being tested in several studies of ‘in vivo purging’ before high-
dose therapy (Magni et al, 2000; Voso et al, 2000). 
The demonstration of efficacy as a single agent has led to the
investigation of rituximab as a component of combination chemo-
immunotherapy. Whilst it might have been thought that co-
administration with chemotherapy and corticosteroids would 
mitigate the effect of the antibody through disruption of immune
effectors, in practice these misgivings have not been borne out.
Studies in the initial therapy of both follicular and diffuse large cell
lymphomas have shown a very high response rate, with up to 60%
complete responses (Czuczman et al, 1999; Vose et al, 2001), and the
most provocative finding was in the French Groupe d’etudes des
lymphomes de l’adulte (GELA) study (Coiffier et al, 2000). This
randomised patients over the age of 60 with newly diagnosed diffuse
large B-cell lymphoma to conventional chemotherapy (CHOP) or the
same treatment together with rituximab in each cycle. With a median
follow up of 12 months there were significant differences in
response rate, time to progression and overall survival in favour of
the CHOP + rituximab arm (Table 2). Almost all the difference
between the arms appears to derive from an early improvement in
the response rate. On the basis of these results a randomised study
examining a similar question (ECOG study 4494) was closed early
in the United States, although a large study addressing the question
in younger patients continues in Europe (MINT:
http://www.kompetenznetz-lymphome.de/mint/). Similar studies
are being conducted in low-grade lymphoma, in some cases with
second randomisations to maintenance treatment with the antibody
versus observation. 
The combination of anti-CD20 with irradiation has been exten-
sively investigated using murine antibodies as radioconjugates, 
but to date few studies have attempted to use chimeric molecules,
out of concern for their prolonged half-life in vivo and the risk of
high normal tissue doses. A single trial in recurrent low-grade
lymphoma has compared rituximab to radioimmunotherapy (RIT)
using the parent murine antibody (C2-B8) conjugated to 90Y, with
an apparently higher response rate in the radioimmunotherapy 
arm (80 versus 56%: P < 0.002) but apparently no more durable
remissions (Witzig et al, 2000). The difficulty of delivering more
than one dose of RIT with murine antibodies owing to HAMA
responses may restrict the effectiveness of this strategy. 
Apart from the relatively common B-cell lymphomas, rituximab
has also been tested in the treatment of a variety of other entities
such as myeloma, Waldenstrom’s macroglobulinaemia and hairy
cell leukaemia (Hoffman and Auerbach, 2000; Zinzani et al,
2000). Case reports and small series have reported responses in all
of these, but as yet it has not found a definite place in the routine
scheme of management. Post-transplant lymphoproliferative
disease (PTLD) has also been treated with rituximab, which is an
attractive alternative to cytotoxics in patients who are already
immunosuppressed. Several series have been reported, with high
response rates particularly among patients who have Epstein–Barr-
positive disease (Kuehnle et al, 2000). The largest series of 32
patients treated in France reported a 69% response rate, although
the follow up was too short to establish how durable these were
likely to be (Milpied et al, 2000). 
Finally, the prospect that CD20 targeting might modulate
normal B-cell function has led to the testing of rituximab as
therapy for a variety of antibody-mediated autoimmune diseases
such as idiopathic thrombocytopenic purpura, rheumatoid arthritis
and cryoglobulinaemia. There are preliminary reports of efficacy
in some cases, with 3 of 9 corticosteroid refractory patients with
ITP responding to rituximab in one series (Saleh et al, 2000).
Further studies will determine whether or not this is a useful addi-
tion to the treatment of autoimmunity. 
CONCLUSION 
Rituximab has rapidly found applications in the management of
most types of B-cell lymphoma, although at present the evidence
base is unsatisfactory. In low-grade disease it has activity as a
single agent and there is no doubt that responses are seen in
patients for whom other types of treatment have failed, with
minimal associated toxicity. It will be extremely difficult to
conduct convincing randomised trials in this group of patients
when the level of efficacy has been demonstrated so clearly with
phase II studies. In more aggressive lymphoma randomised studies
are being conducted, at least in Europe, and the results will be crit-
ical for determining the future use of the antibody. Better under-
standing of the mechanisms of action may be most helpful in
guiding the use of combination therapy, both with cytotoxics and
possibly other types of immunotherapy. 
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